Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interactions of Gamcemetinib with CYP/Transporter Modulators
NCT04268394Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gamcemetinib in ankylosing spondylitis (AS) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration up to 72 hours and Area Under the Plasma Concentration-Time Curve up to 72 hours. Started Mar 2020; status: completed.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04268394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268394.